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Abstract: Acyclic cucurbit[n]uril molecular containers 1 and 2C3 have previously been shown to strongly bind to the neuromuscular blocking 
agents rocuronium, vecuronium, pancuronium, and cisatracurium in vitro by optical methods and to reverse neuromuscular block in vivo in 
rats. In this paper we study the in vitro binding of a panel of acyclic CB[n]-type receptors toward the four neuromuscular blocking agents and 
acetylcholine to develop structure-binding affinity relationships. The selected variants include those with different aromatic sidewalls (e.g. 
1Me4 with dimethyl o-xylylene walls; 3 with 1,8-linked naphthalene walls), with different glycoluril oligomer lengths (e.g. 4 and 5 based on 
glycoluril trimer), and with different linker lengths between aromatic wall and SO3- solubilizing group (e.g. 2C2–2C4). Based on the analysis of 
complexation induced changes in 1H NMR chemical shift we conclude that the hydrophobic regions of the guests bind in the hydrophobic cavity 
of the hosts with the cationic moieties of the guest binding at the ureidyl C=O portals by ion-dipole and ion-ion interactions. The thermodynamic 
parameters of binding were determined by direct and competition isothermal titration calorimetry experiments. We find that hosts 4 and 5 
based on glycoluril trimer form significantly weaker complexes with the streroidal NMBAs than with the analogues hosts based on glycoluril 
tetramer (1 and 2C3). Similarly, hosts 1Me4 and 3 with different length and height aromatic walls do not exhibit the extreme binding constants 
displayed by 2C3 but rather behave similarly to 1. Finally, we find that hosts 2C2 and 2C4 bind only slightly more weakly to the NMBAs than 
2C3, but retain the ability to discriminate against acetylcholine, and possess higher inherent water solubility than 2C3. Host 2C4, in particular, 
holds potential for future in vivo applications. 
 





HE administration of neuromuscular blocking agents 
(NMBAs) is an essential element of care given to over 
400 million patients per year during surgical procedures in 
operating rooms, intensive care units, and emergency med-
icine departments.[1] Specifically, NMBAs are used during 
general anesthesia to block neuromuscular transmission 
which prevents movement during surgery and optimizes 
surgical conditions. The NMBAs exert their function by 
binding to the Acetyl choline receptor (AChR) at the neuro-
muscular junction.[1,2] The most widely used NMBAs in clin-
ical practice are rocuronium (roc), vecuronium (vec), and 
cisatracurium (cis) (Figure 1).[1] Unfortunately, an esti-
mated 20–50 % of patients that receive NMBAs experience 
postoperative respiratory disfunction that can lead to 
airway obstruction, hypoxia, and longer stays in the post-
anesthesia care unit all of which increase the risk of moral-
ity and healthcare costs.[3] Accordingly, strategies to 
reverse neuromuscular block at the end of surgery are 
important in clinical practice to control costs and improve 
patient outcomes. Classical reversal strategies involve the 
administration of small molecules like neostigmine and 
edrophonium that bind to and inhibit the activity of Acetyl-
choline esterase which increases the concentration of acetyl 
choline (ACh) at the neuromuscular junction to more 
effectively displace the NMBA from the AChR.[4] An alterna-
tive strategy is to directly compete with the AChR for binding 
to the NMBA. This strategy was first implemented in the form 
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high affinity binding to rocuronium (Ka = 1.05 × 107 M–1) in 
water in vitro.[5] In vivo, Sugammadex reverses neuromus-
cular block by sequestering rocuronium and vecuronium in 
the bloodstream, thereby depleting their concentration at 
the neuromuscular junction, and promoting the clearance 
of the Sugammadex•rocuronium complex in the urine.[6] 
Sugammadex has been having a major impact on the clini-
cal practice of anesthesia in Europe since its approval in 
2008, but was only approved by the US FDA in December 
2015 after concerns about allergic reactions and hemor-
ragic side effects had been addressed. Worldwide sales of 
Sugammadex under the tradename BridionTM by Merck 
amounted to $704 million in 2017.[7] Accordingly, when we 
started our work in this area in 2010 we saw a need to 
develop new classes of molecular containers that could act 
as broad spectrum reversal agents (e.g. roc, vec, and cis).[8]  
 Our group has a long-standing interest in the synthe-
sis and molecular recognition properties of macrocyclic 
cucurbit[n]uril (CB[n]) molecular containers (Figure 1).[9] 
CB[n] are pumpkin shaped hosts that comprise n glycoluril 
units connected by 2n methylene brides that feature a 
hydrophobic cavity guarded by two symmetry equivalent 
electrostatically negative ureidyl C=O portals.[10] Guest 
compounds that feature a hydrophobic region flanked by 
two ammonium moieties can form extraordinarily tight 
complexes (Ka up to 1017 M-1) with CB[n] hosts.[11] Accord-
ingly, we and others, have considered the use of CB[n]-type 
receptors as potential reversal agents for NMBAs.[8a,12] 
Unfortunately, the CB[n] that are large enough to encapsu-
late the steroidal nucleus of roc and vec (CB[8] and CB[10]) 
display low μM solubility in water[10b,13] which greatly limits 
their potential in vivo applications. CB[7] which does have 
good water solubility (20 mM)[10b] was shown by Macartney 
to bind to the ammonium end groups of steroidal NMBAs 
rather than engulf the steroid ring system.[12b] Over the 
years, our group has sought to understand the mechanism 
of CB[n] formation and use that knowledge to prepare new 
CB[n] type receptors with enhanced solubility and clickable 
functional groups.[9b,14] For example, we prepared acyclic 
CB[n]-type receptors (e.g. 1 and 2, Figure 2) that comprise 
a central glycoluril tetramer, two aromatic sidewalls, and 
four sodium sulfonate groups to greatly improve aqueous 
solubility.[15] Related receptors that lack the SO3– solubiliz-
ing groups have also been studied by Sindelar and co-work-
ers.[16] Initially, we studied the ability of 1 and 2 to function 
as solubilizing agents for insoluble drugs and carbon nano-
tubes and as components of sensing arrays for pharmaceu-
tical agents.[15,17] As part of follow-up studies of the use of 
1 and 2 to function as solubilizing excipients, we had cause 
to prepare numerous structural variants containing differ-
ent numbers of glycoluril rings (1, 2, 3, 4),[17d] different 
aromatic walls,[17b] and different solubilizing group linker 
lengths[18] including compounds 1–5 shown in Figure 2. In 
2012, we reported that 1 and 2 bind to roc, vec, and cis in 
vitro with μM to nM binding affinity.[8a] In vivo experiments 
(rat) showed that 1 or 2 reverse the effects of roc, vec, and 
cis in a dose dependent manner and restores the train-of-
four (TOF) ratio faster than placebo and neostigmine and 
comparable to or faster than Sugammadex.[8b,8c] As part of 
our efforts to further develop 2 as a broad spectrum rever-
sal agent for NMBA reversal we studied the binding of 2 
toward a panel of 27 drugs commonly used during or after 
surgery by experiment and simulation to assess the poten-
tial for displacement interactions that could lead to unde-
sired recurarization.[8d] Most recently, we have investigated 
the ability of 1 and 2 to act as in vivo sequestration agents 
for drugs of abuse (e.g. methamphetamine).[19] In a com-
plementary line of inquiry, the group of Ruibing Wang has 
pursued the use of macrocyclic cucurbiturils as reversal 
agents.[20] In this paper, we measure the binding affinity of 
a panel of previously prepared acyclic CB[n] type receptors 
(1–5) toward the panel of NMBAs (roc, vec, pan, cis) and 
acetylcholine (ACh) to more fully define the structure–
binding affinity relationships. 
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Hosts 1–5 were prepared by the literature proce-
dures.[15,17a,17b,17d] The neuromuscular blocking agents (roc, 
vec, pan, and cis) and ACh were purchased from commer-
cial suppliers and used without further purification. 1H NMR 
spectra were measured on commercial NMR spectrome-
ters operating at 400 MHz. ITC data was collected on a 
Malvern Microcal PEAQ-ITC instrument with a 200 µL cell 
volume. We used an injection syringe of 40 μL capacity. In 
each case, the host and guest solutions were prepared in a 
20 mM NaH2PO4 buffer (pH 7.4). The sample cell was filled 
to capacity (200 μL) with the host solution and the guest 
solution was titrated (first injection = 0.4 μL, subsequent 18 
injections = 2 μL) into the cell. Competition (displacement) 
titrations were performed for container•drug complexes 
with binding constants exceeding Ka = 5 × 106 M–1 using 
CHDA as a weaker binding ligand included with the host in 
the ITC cell. Data was fitted, as appropriate, with either the 
single set of sites model or the competitive binding model 
within the MicroCal PEAQ-ITC analysis software. 
 
RESULTS AND DISCUSSION 
This results and discussion section is organized as follows. 
First, we describe the rationale for our selection of the eight 
different hosts used in this study. Next, we present the 
results of 1H NMR experiments that provide qualitative 
information on the geometry of the host•guest complexes. 
Subsequently, we present the results of isothermal titration 
calorimetry experiments used to measure the thermody-
namic parameters for the various host•guest complexes. 
Finally, we discuss the trends in the Ka values as a function 
of host structure. 
Selection of Hosts 1–5  
As described above, our investigations into the use of acy-
clic CB[n]-type compounds as reversal agents have 
focussed on lead compounds 1 and 2 due to their high bind-
ing affinity and their excellent biocompatibility in vitro and 
in vivo (e.g. high maximum tolerated dose, no hERG activ-
ity, no genotoxicity).[15,18,21] In addition to 1 and 2, we also 
selected compounds 1Me4 and 3 that feature dimethyl o-
xylylene and 2,7-dialkoxynaphthalene sidewalls. These 
structural changes influence the depth (e.g. 3 is deeper), 
the size (e.g. 1Me4 is intermediate in size between 1 and 2), 
and the nature (e.g. the aliphatic Me groups of 1 become 
part of the walls that define the molecular recognition sur-
face) of the cavity. Finally, we selected compounds 4 and 5 
that differ from 1 and 2 in that they are based on a central 
glycoluril trimer but possess common aromatic side-
walls.[17d] The cavities of hosts 4 and 5 are smaller than 
those of 1 and 2 and may be more complementary to the 
narrower diammonium region of cis.[17d] Finally, we se-
lected compounds 2C2 and 2C4 which differ in the length 
of the alkylene linker between the aromatic sidewall and 
the solubilizing sulfonate groups.[18] Previously, 2C2 (68 
mM) and 2C4 (196 mM) have been shown to have higher 
aqueous solubility than 2 (14 mM) which would be advan-
tageous for formulation if the binding constants of 2C2 or 
2C4 were comparable to those of 2 toward the NMBAs. 
1H NMR Investigations of the Host-
Guest Complexes 
Initially, we performed qualitative 1H NMR investigations of 
the interactions between containers 1–5 and guests (roc, 
vec, pan, cis, ACh, and CHDA) to glean information about 
complex geometry and stoichiometry. It is well known that 
the ureidyl C=O region of macrocyclic CB[n] and acyclic 
CB[n]-type receptors constitute ammonium ion binding 
regions due to ion-dipole interactions.[10a,22] Conversely, 
the cavity of macrocyclic CB[n] and acyclic CB[n]-type 
receptors constitutes a hydrophobic binding region; the 
cavity is also a magnetic shielding region by virtue of the π-
systems of the glycoluril units and the aromatic side-
walls.[9b,23] In accord with these expectations, the 1H NMR 
spectra of complexes between hosts 1–5 and guests ACh 
and CHDA (Supporting Information) feature significant 
upfield shifting for the methylene protons of ACh and CHDA 
which indicates they are located in the cavity of the host. 
Somewhat surprisingly, the NMe3 protons of ACh also 
undergo an upfield shifting which probably reflects an out-
 
Figure 2. Chemical structures of acyclic CB[n]-type receptors 
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of-plane geometrical helical distortion of the hosts which 
allows the NMe3+ group to engage in cation-π interactions 
with the aromatic sidewalls of the hosts. Figure 3a-c show 
the 1H NMR spectra recorded for cis, 2C2, and an equimolar 
mixture of cis and 2C2. Upon formation of the 2C2•cis com-
plex we observe a large upfield change in chemical shift for 
Hcc and Hdd which means that host resides in large part on 
the central (CH2)5 linker between the benzyl isoquinoline 
units as expected. Conversely, we observe a significant 
downfield change in chemical shift of Ha and Hb on the 
naphthalene sidewalls of 2C2 upon complex formation. We 
attribute this change to the presence of intramolecular 
edge-to-face π-π interactions between the naphthalene 
walls of uncomplexed 2C2 which are disrupted upon com-
plex formation.[17b] Related downfield changes in chemical 
shift of the protons on the aromatic sidewalls are also seen 
for hosts 1, 2, and 3.[17b] For other host-guest combinations, 
multiple resonances are observed for the aromatic walls 
upon complexation. For example, upon formation of the 
3•pan complex (Figure S54) we observe that the two sym-
metry equivalent aromatic protons (Ha and Hb) of C2v-3 split 
into 8 resonances which reflects the overall C1-symmetry of 
 
 
Figure 3. 1H NMR spectra recorded (400 MHz, RT, D2O) for solutions containing: a) cis (1 mM), b) cis (1 mM) and 2C2 (1 mM), 
c) 2C2 (1 mM), d) vec (1 mM), e) 1Me4 (1 mM) and vec (2 mM), f) 1Me4 (1 mM) and vec (2 mM), and g) 1Me4 (1 mM). 
 
 





 D. SHAYA and L. ISAACS: Acyclic Cucurbit[n]uril-Type Containers … 167 
 




the 3•pan complex due to enantiomerically pure pan guest 
and slow guest exchange kinetics. For the 5•vec and 5•pan 
complexes (Figures S57 and S60) we observe splitting of the 
two aromatic resonances of C2v-5 (Ha and Hb) into four res-
onances (rather than eight) because fast guest exchange 
kinetics averages the two possible orientations (e.g. up or 
down) of vec or pan within the cavity of 5. Related 
increases in the number of resonances are observed for the 
CH2-groups of the glycoluril backbone of C2v-5 (e.g. two 
doublets from 5.0–5.5 ppm; Figure S57) upon formation of 
the 5•vec complex (e.g. four doublets from 5.0 – 5.6 ppm). 
Figure 3d-g show the 1H NMR spectra recorded for vec, 
1Me4, and 1 : 1 and 1 : 2 mixtures of 1Me4 and vec. As 
expected, at a 1 : 1 ratio of 1Me4:vec, we observe significant 
upfield shifts for the axial steroidal CH3-groups (Hgg, Hhh) 
which indicates that the steroidal nucleus of vec is bound 
inside the cavity of 1Me4 which allows the pendant ammo-
nium groups to engage in ion-ion and ion-dipole interac-
tions with the C=O portals and SO3- solubilizing groups of 
the host. At a 1 : 2 ratio of 1Me4:vec the resonances for the 
axial steroidal Me groups are broadened into the baseline 
which indicates that exchange processes with intermediate 
kinetics occur on the 1H NMR timescale. Figure 4 shows a 
cross-eyed stereoview of an MMFF minimized geometry  
of the 1Me4•vec complex which illustrates the three 
dimensional arrangement of vec inside the cavity of the 
host. Interestingly, the axial Me-groups point into the 
concavity shaped by the glycoluril tetramer whereas the 
axial steroidal C-H bonds on the α-face are oriented toward 
the aromatic walls of the host. Overall, our analysis of the 
changes in 1H NMR chemical shifts upon complexation are 
consistent with the complexation of the hydrophobic 
portions of the guests within the hydrophobic cavity of the 
acyclic CB[n]-type receptors with electrostatic interactions at 
the portals as expected based on the literature prece-
dents.[9b,22]  
Determination of the Thermodynamics 
of Host•Guest Complexes by Isothermal 
Titration Calorimetry 
After having observed clear cavity binding of the NMBA 
guests within the cavity of hosts 1–5 by 1H NMR spectros-
copy, we set out to determine the strength and thermody-
namic parameters of the complexes. Given that the tight 
binding previously observed with 2[8a] and the complexity 
and broadening observed in the 1H NMR of many of the 
complexes would complicate Ka determination by 1H NMR 
spectroscopy we decided to use ITC which would deliver 
the full thermodynamic parameters. Table 1 presents the 
Ka, ΔrG, ΔrH, and TΔrS values for the various host•guest 
complexes. For the weaker complexes (e.g. Ka ≤ 5 x 106 M–1) 
we were able to perform direct titrations of host with 
guest. For example, Figure 5a shows the thermogram 
obtained when a solution of 2C4 (70 μM) in the cell was ti-
trated with a solution of CHDA (1 mM) in the syringe. Fitting 
of the data to a 1 : 1 binding model implemented within the 
PEAQ-ITC analysis software allowed a determination of Ka = 
1.00 × 106 M-1 and ΔrH = –3.59 kcal mol–1; complexation is 
 
 
Figure 5. Thermograms recorded (298.0 K, 20 mM sodium 
phosphate buffered H2O, pH 7.4) during the titration of: a) 
a solution of 2C4 (70 μM) with a solution of CHDA (1 mM) in 
the syringe, and c) a solution of 2C4 (100 μM) and CHDA 
(500 μM) in the cell with a solution of Roc (1.08 mM) in the 
syringe. The data was fitted using the PEAQ-ITC analysis 
software to: b) a one-set-of-sites binding model to extract 
the thermodynamic parameters for 2C4•CHDA, and d) to a 
competitive binding model using the thermodynamic 
parameters for 2C4•CHDA as inputs to determine the 
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also entropically favourable with –TΔrS = –4.59 kcal mol–1. 
For complexes with higher Ka values, direct titrations are 
not reliable because the c-values are larger than 1000.[24] 
Accordingly, to measure Ka > 107 M–1 we performed 
competitive ITC titrations. In competitive ITC titrations, a 
solution of host and weak binding guest (Ka and ΔrH 
previously determined) in the cell is typically titrated with a 
solution of the tighter binding guest.[25] As the guest 
exchange process occurs, the difference in ΔrH between the 
two competing complexes is evolved so it is important to 
select the competitor wisely. We have found that CHDA is 
a suitable competitor in many cases. Figure 5c shows the 
thermogram obtained during the titration of a solution of 
2C4 (70 μM) and CHDA (0.5 mM) with a solution of roc (1.08 
mM) in the syringe. Figure 5d shows the fitting of the data 
to a competitive binding model using the known 
thermodynamic parameters for the 2C4•CHDA complex 
(Figure 5b) as inputs which allowed us to determine Ka = 
1.32 × 109 M–1 and ΔrH = –17.1 kcal mol–1 for the 2C4•roc 
complex. The thermodynamic parameters for the 
remaining host•guest complexes (Table 1) were measured 
by analogous direct or competitive ITC titrations as 
documented in the Supporting Information. 
 
DISCUSSION OF THE THERMODYNAMIC PARAMETERS 
There are a number of interesting trends observed in the 
thermodynamic parameters of binding that are worthy of 
discussion. First, and most relevant toward the proposed 
use of 2C3 as an in vivo reversal agent for steroidal neuro-
muscular blocking agents is that 2C3 displays nanomolar 
affinity toward roc, vec, and pan and displays 4–20-fold 
higher affinity than either 2C2 or 2C4. Figure 6 presents the 
thermodynamic data in bar chart form to allow straightfor-
ward comparisons. Host 2C3 has previously been found to 
be a more efficient solubilizing agent for insoluble drugs 
which can be traced to its higher binding constants than 
2C2 and 2C4 in accord with present results.[18] Hosts 1, 
1Me4, and 3–5 display lower affinity (2 × 104 – 5 × 106 M–1) 
toward roc, vec, and pan. Amongst these three steroidal 
NMBA’s pan usually forms the weakest complex which is 
surprising given that pan contains two permanent quater-
nary ammonium groups which would be expected to 
enhance binding.[11d] Host 2C3 binds roc 32000-fold 
stronger than ACh which is important because the seques-
tration of ACh from the neuromuscular junction is undesir-
able. In this regard, it is worth noting that 2C4 (2C2) is 
22000-fold (6900-fold) selective for roc over ACh while 
maintaining sub nM affinity toward roc. Host 2C4 has 
higher inherent solubility (196 mM) than 2C3 (14 mM) and 
2C2 (68 mM) which suggests that 2C4 may be more easily 
formulated for potential in vivo use.[18]  
 Part of the impetus to perform this structure–bind-
ing affinity study was to determine whether superior acyclic 
CB[n]-type receptors could be discovered for the benyli-
soquinoline NMBA cis which is the third most popular 
NMBA in clinical use. We hoped that the narrow (CH2)5 
chain of the guest would thread more efficiently through 
Table 1. Thermodynamic parameters (Ka (M–1), ΔrH, ΔrG, and 
–TΔrS (kcal mol–1) and determined for the host•guest 
complexes by ITC. [a] competition ITC titration using CHDA 
as competitor. 
Ka / 106 / M–1; ΔrH / kcal mol–1; ΔrG / kcal mol–1; –TΔrS / kcal mol–1 
 CHDA ACh roc vec pan cis 
1 Ka 2.30 0.0229 3.51 4.2 0.758 0.132 
ΔrH –5.69 –6.87 –8.64 –5.56 –4.35 –16.4 
ΔrG –8.68 –5.95 –8.93 –9.05 –8.02 –6.99 
–TΔrS –2.99 0.917 –0.291 –3.49 –3.67 9.40 
1Me4 Ka 0.730 0.0302 2.51 5.41 1.41 0.0914 
ΔrH –6.91 –6.31 –14.9 –6.68 –5.46 –10.1 
ΔrG –8.00 –6.41 –8.73 –9.19 –8.39 –6.77 
–TΔrS –1.09 –1.17 6.21 –2.51 –2.93 3.30 
2C2 Ka 2.00 0.158 1090[a] 862[a] 148[a] 0.13 
ΔrH –6.64 –8.32 –16.1 –9.29 –8.69 –13.2 
ΔrG –8.60 –7.09 –12.3 –12.2 –11.1 –6.83 
–TΔrS –1.96 1.23 3.74 –2.90 –2.46 6.35 
2C3 Ka 2.49 0.179 5780[a] 4020[a] 800[a] 0.128 
ΔrH –5.05 –7.27 –13.5 –9.33 –9.31 –13.3 
ΔrG –8.73 –7.17 –13.3 –13.1 –12.1 –6.97 
–TΔrS –3.68 0.102 0.201 –3.77 –2.84 6.34 
2C4 Ka 1.00 0.0588 1320[a] 231[a] 200[a] 0.194 
ΔrH –3.59 –4.57 –17.1 –6.26 –6.11 –10.9 
ΔrG –8.19 –6.51 –12.4 –11.4 –11.3 –7.21 
–TΔrS –4.59 –1.94 4.65 –5.15 –5.21 3.64 
3 Ka 0.140 
n.b. 
0.847 0.971 0.195 0.0971 
ΔrH -4.79 –9.05 –4.15 –4.68 –8.30 
ΔrG -7.02 –8.09 –8.17 –7.22 –6.80 
–TΔrS -2.24 0.967 –4.02 –2.53 1.49 
4 Ka 
n.d. 
0.000704 0.0214 0.0348 0.0382 0.0225 
ΔrH –4.99 –6.08 –3.67 –4.01 –6.69 
ΔrG –3.88 –5.91 –6.20 –6.25 –5.94 
–TΔrS 1.11 0.173 –2.53 –2.24 0.754 
5 Ka 
n.d. 
0.0015 1.31 0.98 0.588 0.0562 
ΔrH –3.78 –7.21 –4.89 –3.63 –7.06 
ΔrG –4.33 –8.35 –8.18 –7.87 –6.48 
–TΔrS –0.555 –1.14 –3.28 –4.24 0.582 
n.d.: not determined because competition experiments were not necessary. 
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the narrower hosts 4 and 5 created from glycoluril trimer 
or host 3 with taller sidewalls. Experimentally, we found 
that 1–3 bound cis with Ka values in the 105 M–1 range and 
that 4 and 5 do so even more weakly with Ka values from 
22500–56200 M–1. Host 2C4 displays highest affinity 
toward cis and possesses excellent aqueous solubility. 
Interestingly, the host•guest complexes with cis are all 
entirely driven by favourable enthalpic changes and feature 
entropically unfavourable contributions to ΔrG. We believe 
that the conformational restriction of the long oligometh-
ylene chain of cis needed to optimize binding is responsible 
for this thermodynamic signature. 
 Comparison between structurally related hosts 
toward common guests is also worthwhile. For example, 
hosts 1 and 2C3 are homologues of 4 and 5 containing one 
more glycoluril ring. This additional glycoluril ring was ex-
pected to increase the size (volume) of the host cavity and 
thereby influence binding affinity. Experimentally, we find 
that 1 is a significantly better host than 4 toward roc (164-
fold), vec (121-fold), pan (20-fold), cis (6-fold), and ACh 
(32-fold). Similarly, we find that 2C3 is a significantly 
better host than 5 toward roc (4400-fold), vec (4100-fold), 
pan (1360-fold), cis (2.3-fold), and ACh (119-fold). We 
believe the superior affinity and selectivity displayed by 1 
and 2C3 reflects the larger cavity size / volume which 
probably contains a larger number of high energy 
waters[23] that provide an enhanced driving force for 
complexation. Selectivity is lowest for the narrow cis 
guest which probably reflects a better complementarity 
between the narrow host with the narrower guest. A 
related comparison can be made between the behaviour 
of hosts 2C3 and 3 which are isomers of one another. Host 
2C3 with its 2,3-linked naphthalene sidewalls possesses a 
wider cavity, but host 3 with its 1,8-linked naphthalene 
sidewalls possesses a narrower but deeper cavity. The 
SO3– solubilizing groups of 3 are also farther from the 
cavity and ureidyl C=O portals of the host. Experimentally, 
we find that 2C3 is a better host than 3 for roc (6800-fold), 
vec (4100-fold), pan (4100-fold), and cis (1.3). Once again, 
the selectivity is largest for the larger steroidal guests that 
can properly fill the larger cavity of 2C3 without requiring 
conformational changes of the host and lowest for cis 
whose (CH2)5 chain is more complementary to the 
narrower cavity of 3. Finally, one can consider the binding 
trends for hosts 1, 1Me4, and 2C3 which differ sys-
tematically in the length of their aromatic sidewalls. For 
the smaller guests CHDA, ACh, and cis only small 
differences (1.4–7.8-fold) are observed in the binding 
constants toward 1, 1Me4, and 2C3 whereas for the larger 
steroidal guests roc, vec, and pan the differences are 
much larger (434–1055-fold). Our interpretation is that 
the cavity of 2C3 is particularly poorly solvated (e.g. high 
energy waters) and is able to adjust its conformation (e.g. 
helical twist) to fully complement the larger steroidal 
guest in ways that are not possible for small hosts and not 
needed for the smaller guests. As found in previous 
studies,[17b,17d,18] hosts 2C2–2C4 are the most potent hosts 
known to date in the acyclic CB[n] series. 
 
CONCLUSION 
In summary, we have studied the interaction of a series of 
acyclic cucurbit[n]uril-type receptors (1–5) toward four 
NMBAs, ACh, and CHDA to further define the structure–
binding affinity relationships relevant for their develop-
ment as in vivo reversal agents. Based on the result of  
 
Figure 6. Bar chart depicting the thermodynamic parameters of binding (ΔrG, red bars; ΔrH, green bars; –TΔrS, blue bars) in  
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1H NMR experiments, we conclude that the NMBAs bind 
with their hydrophobic residues located in the hydrophobic 
cavity of 1–5 which places their cationic moieties at the ure-
idyl C=O portals of the hosts. Isothermal titration calorime-
try was used to measure the thermodynamic parameters 
for binding between hosts 1–5 and the NMBAs and ACh. 
We find that host 2C3 and its relatives 2C2 and 2C4 display 
nanomolar affinity toward the steroidal NMBAs and main-
tain a high selectivity against ACh as needed for the pro-
posed in vivo use. Hosts 2C4 and 2C2 with their higher 
aqueous solubility compared to 2C3 are viable alternative 
reversal agents for steroidal NMBAs. All eight hosts dis-
played affinities toward cis in the 2 × 104 – 2 × 105 M–1 range 
according to ITC. No binding improvement relative to com-
pound 1 (Ka = 1.32 × 105 M–1 toward cis) which was previ-
ously used to reverse cis in vivo in rats[8b] was found. Finally, 
hosts 4 and 5 which are based on glycoluril trimer units 
rather than tetramer units (e.g. 1 and 2) display 20–4400-
fold weaker binding to the steroidal NMBAs which we at-
tribute to the smaller host cavity and a small number of 
high energy waters[23] which are known to provide a driving 
force in CB[n] complexation. Amongst the acyclic CB[n] 
tested, we conclude that 2C3 and its analogues 2C4 and 2C2 
remain the most promising agents for further development 
as in vivo reversal agents for neuromuscular blocking agents. 
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